Click here to read the articles and download the PDF

Pharmaceutical Commerce - December 2024

Because of the potential for product shortages at pharmacies, the FDA has not only given industry more time for compliance—but time to catch up on boosting the supply chain’s interoperable efforts.

Did Industry Fumble the DSCSA Deadline?

A crash course on the bubble itself, including therapeutic areas most affected.

Going Inside the Gross-to-Net Bubble and Its Nuances

Addressing the bottlenecks in cell and gene therapy manufacturing through a well-designed artificial intelligence approach is essential to avoiding data siloes.

Why AI Advances in CGT Require Getting Data Right

Videos

In the fourth part of this roundtable discussion, key opinion leaders discuss how successful RFID use cases in the food sector can translate well to pharma, including what needs to be implemented in order to see success. 

Peer Exchange: Learning from Other Industries (Episode 4)

Bill Trombetta, PhD, professor, healthcare strategy, marketing, St. Joseph's University, discusses the breakout session at Trade & Channel Strategies in Philadelphia.

Trade & Channel Strategies 2024: Industry Audit—Analyzing Top Biopharmaceuticals Performance Metrics

Articles

A session provides considerations for manufacturers during development, rollouts, and implementation, specifically as it pertains to the HSSP perspective.  

Trade & Channel Strategies 2024: Lessons Learned and Considerations with Humira

Kevin O’Meara discusses Patient-Cetric 3.0 breakout session and the challenges of drug manufactures implementing Direct-to-Patient models.

Trade & Channel Strategies 2024: Key Challenges of Implementing Direct-to-Patient Models 

A session investigates the drivers of these shortages and ways to mitigate them. 

Trade & Channel Strategies 2024: A Deep Dive into Drug Shortages

The latest news for pharma industry insiders.

Pharma Pulse 12/12/24: AI Skepticism to Adoption in Pharma Marketing, Biologic Treatments Transforming Severe Asthma Management & more

Breakout session explores how direct-to-patient models shorten the time to diagnosis and therapy to improve patient outcomes.

Trade & Channel Strategies 2024: Patient-Centric 3.0 — How Direct-to-Patient is the New Commercialization Model

The seminar focuses on US supply chain resiliency, while remaining compliant and preserving patient access.

Trade & Channel Strategies 2024: Protecting the Pharma Supply Chain

A case study explores a way to potentially transform commercial organizations, while driving revenue growth.

Featured Content

Pharmaceutical Commerce - December 2024

Did Industry Fumble the DSCSA Deadline?

Going Inside the Gross-to-Net Bubble and Its Nuances

Why AI Advances in CGT Require Getting Data Right